Sometimes it takes a dramatic success story to bring a university into biotech. Jim Hayward, currently of Applied DNA Sciences, describes how Barry Coller of the Department of Hematology at Stony Brook developed “what was really the first blockbuster monoclonal antibody, a drug called ReoPro” that “reversed the effects of platelet-dependent strokes… It became used in high-risk angioplasty, and it was licensed to Lilly and became the largest licensing revenue in the history of Stony Brook University, but was also their first real toe into biotech commerce.” At that point, in the early 1980s, many scientists viewed biotech ventures with skepticism, and “Barry was quite courageous in being amongst the first to do that…it changed everyone’s mind. Now everyone wanted to do it.” [laughs]